Shun Lu, MD
Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai Chest Hospital, China · Shanghai Chest Hospital of Shanghai Jiao Tong University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shun Lu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:57 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07668752 · A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationGenfleet Therapeutics (Shanghai) Inc. · recruiting · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer) · principal investigator
- Ph1NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung CancerShanghai AbelZeta Ltd. · recruiting · Squamous Cell Lung Cancer · principal investigator
- Ph1NCT07110363 · A Clinical Study of BT02 in Treating Patients With Advanced Lung CancerBiotroy Therapeutics · not yet recruiting · Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT06737081 · SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesShenzhen Salubris Pharmaceuticals Co., Ltd. · recruiting · Anemia · principal investigator
- Ph1/Ph2NCT06500676 · A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D MutationsGenfleet Therapeutics (Shanghai) Inc. · recruiting · KRAS G12D Mutations, Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT06345482 · A Study of MHB039A for Advanced Solid TumorMinghui Pharmaceutical (Hangzhou) Ltd · active not recruiting · Advanced Solid Tumor · principal investigator
- Ph2NCT06147570 · A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerJiangsu Hansoh Pharmaceutical Co., Ltd. · recruiting · Nonsmall Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05951608 · A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsAkeso · active not recruiting · Advanced Solid Tumors · principal investigator
- Ph1NCT05430386 · Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05383898 · Study to Evaluate D-1553 in Subjects With Lung CancerInventisBio Co., Ltd · completed · NSCLC · principal investigator
- Ph1/Ph2NCT05207787 · Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph2NCT05141786 · A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).Shanghai Miracogen Inc. · unknown · Non-small- Cell Lung Cancer (NSCLC) · principal investigator
- Ph1NCT05055232 · A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerXuanzhu Biopharmaceutical Co., Ltd. · completed · ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer · principal investigator
- Ph3NCT05015608 · Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationHutchison Medipharma Limited · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04923906 · Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsJiangsu Hansoh Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04923945 · Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsHutchison Medipharma Limited · completed · Non-small Cell Lung Cancer Metastatic · principal investigator
- Ph2NCT03777124 · Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd. · terminated · NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody · principal investigator
- Ph3NCT03521154 · A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)AstraZeneca · active not recruiting · Non Small Cell Lung Cancer (Stage III) · principal investigator
- N/ANCT03059641 · Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaGeneplus-Beijing Co. Ltd. · completed · Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung · principal investigator
- N/ANCT02980536 · cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia ChinaBerry Genomics Co., Ltd. · unknown · Nonsmall Cell Lung Cancer, Adenocarcinoma · study chair
- Ph2NCT02027090 · High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT01404260 · Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung CancerGuangdong Association of Clinical Trials · completed · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.